Therapy of osteoarthritis with crystalline glucosamine sulphate / A review of the clinical efficacy;Kristallines glucosaminsulfat in der therapie der arthrose / Übersicht zur klinischen wirksamkeit

Arzneimittel-Forschung/Drug Research

Volumn 57, Issue 4, 2007, Pages 203-217

  Heisel, Jürgen ^a   Förster, Klaus K ^b  

^a Orthopädische Abteilung der Fachkliniken Hohenurach   (Germany)

^b Opfermann Arzneimittel GmbH   (Germany)

Author keywords

Antiosteoarthritic drug; CAS 29031 19 4; Dona ; Glucosamine sulphate, clinicai trials; Interleukin 1; Osteoarthritis, disease modification, joint space narrowing, structure modification, symptom modification

Indexed keywords

CYTOKINE; GLUCOSAMINE SULFATE; IBUPROFEN; INTERLEUKIN 1; PIROXICAM; PLACEBO;

CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG FORMULATION; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; OSTEOARTHRITIS; REVIEW;

EID: 34248139650     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296607     Document Type: Review

References (82)

1. Grifka J. Kniegelenksarthrose: Epidemiologie, arthroskopische Therapie, Kernspintomographie, Knieschule. Stuttgart - New York: Georg Thieme Verlag; 1994.
2. Pendleton A, Arden M, Dougados M, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2000;59:936-944
3. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum. 1998;41:1343-1355.
4. Oliveira SA, Felson DT, Reed JI, et al. Incidence of symptomatic hand, hip and knee osteoarthritis among patients in a health maintainance organisation. Arthritis Rheum. 1995;38:1134-1141.
5. Guccione AA, Felson DT, Anderson JJ, et al. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Public Health. 1994;84:351-358.
6. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum. 2000;43:1905-1915.
7. Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145-1155.
8. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2005;64:669-681.
9. Towheed TE, Maxwell I, Judd MG, et al. Acetaminophen for osteoarthritis. The Cochrane Database of Systematic Reviews. Issue 1. 2006:Art. No.:CD004257.pub2. DOI: 10.1002/ 14651858.
10. Bjordal JM, Ljunggren AE, Klovning A, Slordal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritis knee pain: metaanalysis of randomised placebo controlled trials. Brit Med J. 2004;329:1317-1322.
11. Hamerman D. The biology of osteoarthritis. N Engl J Med. 1989;320:1322-1330.
12. Herrero-Beaumont G, Rovati LC. The use of crystalline glucosamine sulfate in osteoarthritis. Future Rheumatol. 2006;1(4):397-414.
13. Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. The Cochrane Database of Systematic Reviews, Issue 2. 2005;Art. No.: CD002946.pub2.DOI: 10.1002/14651858.
14. Setnikar I, Rovati LC. Absorption, Distribution, Metabolism and Excretion of Glucosamine Sulfate: A review. Arzneimittel-Forschung (Drug Rev.). 2001;51:699-725.
15. Aghazadeh-Habashi A, Settari S, Pasutto FM, Jamali F. Single dose pharmacokinetics and bioavailability of glucosamine in the rat. J Pharm Pharmaceut Sci. 2002;5:181-184.
16. Adebowale A, Du J, Liang Z, Leslie JL, Eddington ND. The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. Biopharm Drug Dispos. 2002;23:217-235.
17. Du J, White N, Eddington ND. The bioavailability and pharmacokinetics of glucosamine hydrochloride and chondroitin sulfate after oral and intravenous single dose administration in the horse. Biopharm Drug Dispos. 2004;25:109-116.
18. Laverty S, Sandy JD, Celeste C, et al. Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses. Arthritis Rheum. 2005;52:181-191.
19. Biggee BA, Blinn CM, McAlindon TE, Nuite M, Silbert JE. Low levels of human Serum glucosamine after ingestion of glucosamine sulfate relative to capability for peripheral effectiveness. Ann Rheum Dis. 2006;65:222-226.
20. Persiani S, Roda E, Rovati LC, et al. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage 2005;13:1041-1049.
21. Persiani S, Locatelli M, Fiorentino S, Rovati LC, Roda A. Absolute bioavailability of glucosamine after administration of crystalline glucosamine sulfate in rats. Osteoarthritis Cartilage. 2005;13(Suppl. A):P161.
22. Persiani S, Rotini R, Trisolino G, et al. Glucosamine plasma and synovial fluid concentrations before and after oral administration of crystalline glucosamine sulfate in knee osteoarthritis patients. Arthritis Rheum. 2005;52(Suppl. 9):1342.
23. 35S-sulfate with cultured human chondrocytes to determine the effect of glucosamine concentration on formation of chondroitin sulfate. Arthritis Rheum. 2004;50:3574-3579.
24. Piepoli T, Zanelli T, Letari O, et al. Glucosamine sulfate inhibits IL-1β-stimulated gene expression at concentrations found in humans after oral intake. Arthritis Rheum. 2005;52(Suppl. 9):1326.
25. Jackson CG, Plaas AH, Barnhill JG, Harris CL, Clegg DO. The pharmacokinetics of oral glucosamine and chondroitin sulfate in humans. American College of Rheumatology meeting late breaking 2005; (Abstract L13).
26. Noyszewski EA, Wroblewski K, Dodge GR, et al. Preferential incorporation of glucosamine into the galactosamine moieties of chondroitin sulfate in articular cartilage explants. Arthritis Rheum. 2001;44:1089-1095.
27. Bassleer C, Rovati LC, Franchimont P. Glucosamine sulfate stimulates proteoglycan production in human chondrocytes in vitro. Osteoarthritis Cartilage. 1998;6:427-434.
28. Piperno M, Reboul P, Helio Le Graverand MP, et al. Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro. Osteoarthritis Cartilage. 2000;8:207-212.
29. Dodge GR, Jimenez SA. Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthritis Cartilage. 2003;11:424-432.
30. Sandy JD, Gamett D, Thompson V, Verscharen C. Chondrocyte-mediated catabolism of aggrecan: aggreganase-dependent cleavage induced by interleukin-1 or retinole acid can be inhibited by glucosamine. Biochem J. 1998; 335:59-66.
31. Altman RD, Cheung H. Glucosamine sulfate on cartilage: lapine study. Arthritis Rheum. 2001;44(Suppl. 9):1535.
32. Tiraloche G, Girard C, Chouinard L, et al. Effect of oral glucosamine on cartilage degradation in a rabbit model of osteoarthritis. Arthritis Rheum. 2005;52:1118-1128.
33. Gouze JN, Bordji K, Gulberti S, et al. Interleukin-1β downregulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1β- mediated effects in rat chondrocytes. Arthritis Rheum. 2001;44:351-360.
34. Shikhman AR, Kuhn K, Alaaeddine N, Lotz M. N-acetylglucosamine prevents IL-1 β-mediated activation of human chondrocytes. J Immunol. 2001;166:5155-5160.
35. Gouze JN, Bianchi A, Becuwe P, et al. Glucosamine modulates IL1-induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF-κB pathway. FEBS Lett. 2002;510:166-170.
36. Largo R, Alvarez-Soria MA, Diez-Ortego I, et al. Glucosamine inhibits IL-1β-induced NF-κB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage. 2003;11:290-298.
37. Alvarez-Soria MA, Largo R, Calvo E, Egido J, Herrero-Beaumont G. Differential anticatabolic profile of glucosamine sulfate versus other anti-osteoarthritic drugs on human osteoarthritic chondrocytes and synovial fibroblast in culture. Osteoarthritis Cartilage. 2005;13(Suppl. A):P309.
38. Uitterlinden EJ, Jahr H, Koevoet JLM, et al. Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage expiants. Osteoarthritis Cartilage. 2006;14:250-257.
39. Hoffer LJ, Kaplan LN, Hamadeh MJ, Grigoriu AC, Baron M. Sulfate could mediate the therapeutic effect of glucosamine sulfate. Metabolism 2001;50:767-770.
40. Cordoba F, Nimni ME. Chondroitin sulfate and other sulfate containing chondroprotective agents may exhibit their effects by overcoming a deficiency of sulfur amino acids. Osteoarthritis Cartilage. 2003;11:228-230.
41. McAlindon TE, La Valley MR Gulin JP Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000;283:1469-1475.
42. Richy F, Bruyere O, Ethgen O, et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis. A comprehensive metaanalysis. Arch Int Med. 2003;163:1514-1522.
43. Noack W, Fischer M, Förster KK, Rovati LC, Setnikar I. Glucosamine sulfate in osteoarthritis of the knee. Osteoarthritis Cartilage. 1994;2:51-59.
44. Rovati LC. The clinical profile of glucosamine sulfate as a selective symptom modifying drug in osteoarthritis: current data and perspectives. Osteoarthritis Cartilage. 1997;5(Suppl. A):72.
45. Müller-Fassbender H, Bach GL, Haase W, Rovati LC, Setnikar I. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage. 1994;2:61-69.
46. Herrero-Beaumont G, Roman JA, Trabado MC, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms. A randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum. 2007;56(2):555-567.
47. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795-808.
48. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine and chondroitin sulfate for knee osteoarthritis. N Engl J Med. 2006;354(20):2184-2185.
49. Houpt JB, McMillan R, Wein C, Paget-Dellio SD. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol. 1999;26:2423-2430.
50. Hochberg MC. Nutritional supplements for knee osteoarthritis - still no resolution. N Engl J Med. 2006;354:858-860.
51. Committee for Proprietary Medicinal Products. Points to consider on clinical investigation of medicinal products used in the treatment of osteoarthritis (CPMP/EWP/784/97). The European Agency for the Evaluation of Medicinal Products. London, UK; 1998.
52. Reginster J-Y, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. Lancet 2001;357:251-256.
53. Pavelka K, Gatterova J, Olejarova M, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis - a 3-year, randomized, placebo-controlled, doubleblind study. Arch intern Med. 2002;162:2113-2123.
54. Bruyere O, Pavelka K, Rovati LC, et al. Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause 2004;11:138-143.
55. Brandt KD, Mazzuca SA, Conrozier T, et al. Which is the best radiographic protocol for a clinical trial of a structure modifying drug in patients with knee osteoarthritis? J Rheumatol. 2002;29:1308-1320.
56. Pavelka K, Bruyere O, Rovati LC, et al. Relief in mild-to-moderate pain is not a confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure-modifying drug trials. Osteoarthritis Cartilage. 2003;11:730-737.
57. McAlindon T. Glucosamine for osteoarthritis: dawn of a new era? Lancet 2001;357:247-248.
58. Brandt KD, Mazzuca SA. Lessons learned from nine clinical trials of disease-modifying osteoarthritis drugs. Arthritis Rheum. 2005;52:3349-3359.
59. Bruyere O, Reginster J-Y, Giacovelli G, Barbetta B, Rovati LC, Pavelka K. Clinical significance of the long-term symptom-modifying effects of glucosamine sulfate. Arthritis Rheum. 2006;54(7):2339-2341.
60. Bruyere O, Compere S, Rovati LC, et al. Five-year follow-up of patients from a previous 3-year randomised, controlled trial of glucosamine sulfate in knee osteoarthritis. Arthritis Rheum. 2003;48(Suppl. 9):89.
61. Pavelka K, Gatterova J, Giacovelli G, Olejarova M, Rovati LC. Glucosamine sulfate prevents total joint replacement in the long-term follow-up of knee osteoarthritis patients. Arthritis Rheum. 2004;50(Suppl. 9):251.
62. Altman RD, Abadie E, Avouac B, et al. Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis. Osteoarthritis Cartilage. 2005;13:13-19.
63. Bruyere O, Honore A, Rovati LC, et al. Radiologic features poorly predict clinical outcomes in knee osteoarthritis. Scand J Rheumatol. 2002;31:13-16.
64. Bruyere O, Honore A, Ethgen O, et al. Correlation between radiographic severity of knee osteoarthritis and future disease progression. Results from a 3-year prospective, placebo-controlled study evaluating the effect of glucosamine sulfate. Osteoarthritis Cartilage. 2003;11:1-5.
65. Hughes R, Carr A. A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee. Rheumatology 2002;41:279-284.
66. McAlindon T, Formica M, LaValley M, Lehmer M, Kabbara K. Effectiveness of glucosamine for symptoms of knee osteoarthritis: results from an internet-based randomised double-blind controlled trial. Am J Med. 2004; 117:643-649.
67. Cibere J, Kopec JA, Thorne A, et al. Randomised, double-blind, placebocontrolled glucosamine discontinuation trial in knee osteoarthritis. Arthritis Care Res. 2004; 51:738-745.
68. McAlindon T, Formica M, Kabbara K, LaValley M, Lehmer M. Conducting clinical trials over the internet: feasibility study. Brit Med J. 2003;327:484-487.
69. Reginster J-Y, Rovati LC, Henrotin Y, et al. Glucosamine sulphate and osteoarthritis. Lancet. 2001;357:1618.
70. Baron AD, Zhu JS, Zhu JH, et al. Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocation in skeletal muscle. Implications for glucose toxicitiy. J Clin Invest. 1995;96:2792-2801.
71. Monauni T, Zenti MG, Cretti A, et al. Effects of glucosamine infusion on insulin secretion and insulin actions in humans. Diabetes 2000;49:926-935.
72. Pouwels MJ, Jacobs JR, Span PN, et al. Short-term glucosamine infusion does not affect insulin sensitivity in humans. J Clin Endocrinol Metab. 2001;86:2099-2103.
73. Tannis AJ, Barban J, Conquer JA. Effect of glucosamine supplementation on fasting and non-fasting plasma glucose and serum insulin concentrations in healthy individuals. Osteoarthritis Cartilage. 2004;12:506-511.
74. Scroggie DA, Albright A, Harris M. The effect of glucosamine-chondroitin supplementation an glycosylated hemoglobin levels in patients with Type 2 diabetes mellitus. A placebo-controlled, double-blinded, randomized clinical trial. Arch Int Med. 2003;163:1587-1590.
75. Rovati LC, Annefeld M, Giacovelli G, Schmid K, Setnikar I. Glucosamine in osteoarthritis. Lancet. 1999;354:1640. Author reply 1641-1642.
76. Anderson JW, Nicolosi RJ, Borzelleca JF. Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food Chem Toxicol. 2005;43:187-201.
77. Marx U, Kausch T, Forster KK. Langzeittherapie der Gonarthrose mit Glucosaminsulfat (dona 200-S Dragees) - eine offene, multizentrische Anwendungsbeobachtung zur intermittierenden Therapie. Orthop Praxis. 2005;41:553-558.
78. Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, 103rd Congress, October 25; 1994.
79. Russell AS, Aghazadeh-Habashi A, Jamali F. Active ingredient consistency of commercially available glucosamine sulfate products. J Rheumatol. 2002;29:2407-2409.
80. Altman RD, Abramson S, Bruyere O, Clegg D, Herrero-Beaumont G, Maheu E, Moskowitz R, Pavelka K, Reginster J-Y. Commentary: osteoarthritis of the knee and glucosamine. Osteoarthritis Cartilage. 2006;14(10):963-966.
81. Förster KK, Heisel J. Medikamentöse Behandlungsstrategien und "Chondroprotektion" bei Knorpelschäden - Update 2004. Orthop Praxis. 2004;40:550-556.
82. Hedges LV. Methods for Meta-Analysis. San Diego: Academic Press; 1985.